Topical roflumilast cream for plaque psoriasis: Initial results from two phase 3 trials announced

Initial results of DERMIS 1 and DERMIS 2 studies comparing roflumilast 0.3% to vehicle cream (placebo) found roflumilast met primary endpoint of Investigator Global Assessment (IGA) success at week 8. [DERMIS 1: 42.4% vs. 6.1% (P<0.0001), DERMIS 2: 37.5% vs. 6.9% (P<0.0001)].

Source:

Biospace Inc.